Drug Trial Radar · NCT05432544
Safety and Tolerability of SHR-1918 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Jul 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
72
Actual
Start
Jun 27, 2022
Primary completion
Dec 11, 2023
Study completion Dec 12, 2023
Sponsor
- Lead sponsor
- Beijing Suncadia Pharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jun 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of this study is to assess the safety and tolerability of SHR-1918 injection in healthy subjects. In addition, this study will provide information on pharmacokinetics and pharmacodynamics of SHR-1918 injection in healthy subjects.
Conditions
- Hyperlipemia
Interventions
SHR-1918Drug
Ascending dose
SHR-1918 placeboDrug
Ascending dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the number of subjects with adverse events (AEs)Time frame: up to day 190
- To assess the number of subjects with serious adverse events (SAEs)Time frame: up to day 190
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.